Rigel Pharmaceuticals, Inc. received milestone payments totaling $1 million from Merck based on progress in the companies’ 2004 collaboration to explore ubiquitin ligases to find treatments for cancer and potentially other diseases. The collaboration with Merck combines Rigel’s capabilities in ubiquitin ligases with Merck’s molecular profiling technology and downstream drug development capabilities. “Merck and Rigel believe the ligase target class represents a potent...